75% Sensitivity Cutpoint | 80% Specificity Cutpoint | Receiver-operating Characteristic (ROC) Curves | ||
---|---|---|---|---|
Area Under the Curve | 95% CI | |||
EQ-5D | ||||
RA | 0 | 0.10 | 0.69 | 0.65–0.73 |
PsA | 0 | 0.18 | 0.68 | 0.61–0.75 |
AS | 0.04 | 0.19 | 0.75 | 0.68–0.82 |
SF-6D | ||||
RA | 0.02 | 0.08 | 0.72 | 0.70–0.74 |
PsA | 0.01 | 0.07 | 0.73 | 0.69–0.76 |
AS | 0.05 | 0.09 | 0.77 | 0.73–0.82 |
Pain VAS | ||||
RA | −4.0 | −19.0 | 0.73 | 0.71–0.75 |
PsA | −8.0 | −19.0 | 0.75 | 0.72–0.79 |
AS | −15.0 | −19.0 | 0.82 | 0.78–0.86 |
Patient global VAS | ||||
RA | −6.0 | −20.0 | 0.74 | 0.72–0.76 |
PsA | −9.0 | −18.0 | 0.76 | 0.73–0.79 |
AS | −16.0 | −17.0 | 0.83 | 0.79–0.87 |
MHAQ | ||||
RA | 0 | −0.25 | 0.71 | 0.69–0.73 |
PsA | 0 | −0.25 | 0.75 | 0.72–0.78 |
AS | −0.13 | −0.25 | 0.75 | 0.71–0.80 |
MCII: Minimal Clinically Important Improvement; DMARD: diseasemodifying antirheumatic drug; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; PASS: Patient Acceptable Symptom State; MHAQ: Modified Health Assessment Questionnaire; VAS: visual analog scale; EQ-5D: EuroQol-5 Dimensions; SF-6D: Short-Form-6 Dimensions.